Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to ...

Forecasts indicate a drastic increase in US obesity rates in the next 25 years, emphasizing the need for comprehensive public ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half ...

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

New discoveries in atherosclerosis pathways have shed light on the active mechanisms in other diseases such as chronic kidney disease (CKD) and HIV, paving the way for furture therapeutics.